NPX125

NPX125 is a first-in-class B7-H7-targeted antibody-drug conjugate (ADC) being developed by NextPoint Therapeutics for the treatment of cancer. It leverages a proprietary linker technology and utilizes a clinically validated topoisomerase 1 inhibitor as its cytotoxic payload, with a drug-antibody ratio (DAR) of 8. The ADC targets the B7-H7 protein, which is highly expressed in various solid tumors, enabling efficient internalization and delivery of the cytotoxic agent into tumor cells. Preclinical studies have demonstrated that NPX125 exhibits potent direct and bystander cytotoxic activity across multiple tumor models with varying levels of B7-H7 expression, robust anti-tumor efficacy in vivo, superior serum stability in pharmacokinetic studies, and strong developability due to its unique antibody selection and linker properties. As of April 2025, NPX125 is in preclinical development with IND-enabling work underway; clinical trials are anticipated to begin following an IND filing expected in mid-2026[1][2].